Overview
- Q3 revenue came in at $698.95 million versus a $700.46 million consensus, while adjusted EPS of $1.18 topped expectations of $1.14.
- The board approved a new two-year $1 billion share repurchase program that replaces the previous authorization.
- Full-year 2025 guidance now calls for adjusted EPS of $4.90 to $5.00, revenue of $2.83 to $2.88 billion, and reaffirmed organic growth of 2% to 4%.
- Life Sciences delivered $342.82 million in revenue with flat organic growth, and Diagnostics generated $356.13 million with 2% organic growth.
- Operating cash flow was $138.5 million, cash stood at $931.4 million, total debt was about $3.21 billion, and shares traded down roughly 2.9% on the day.